Tonix shares soar as PTSD drug shows promise in study – Reuters UK
 Reuters UK | Tonix shares soar as PTSD drug shows promise in study Reuters UK Tonix Pharmaceuticals Holding Corp said a higher dose of its experimental drug for post-traumatic stress disorder (PTSD) helped control symptoms in patients, sending its shares surging 46 percent in premarket trading. A 5.6 mg dose of the drug, TNX-102 … Tonix Pharma’s PTSD candidate for shows positive effects in mid-stage study; shares up 20% premarketSeeking Alpha Tonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic …GlobeNewswire (press release) Tonix Pharmaceuticals Phase 2 trial success for military related PTSDProactive Investors USA & Canada |